On March 26, 2024, Henan Zhimei Pharmaceutical Co., Ltd. received good news that the technology related to the anti-tumor inhibitor BTK-2 developed by the company has been successfully applied for in Japan and China, adding two scientific research and innovation invention patents to the company.

     Both of these patents are innovative technologies obtained during the development of BTK-2, with one being authorized by the Japanese patent agency; One is issued by the China National Intellectual Property Administration of China, with patent number. The ownership of these two invention patents is EMICRO Biomedicine Company.

     Since its establishment, the leadership team of EMICRO Biomedicine Company has attached great importance to protecting its core technology, actively planning patent layout, and encouraging technological innovation. Up to now, multiple patents have been successfully applied for internationally. BTK inhibitors are one of the innovative drug pipelines that the company focuses on developing and participating in international competition due to their effectiveness in treating lymphatic malignancies and other diseases. The company has achieved the most new technologies, achievements, and invention patents around this pipeline, and has also achieved the best results. In recent years, EMICRO Biomedicine Company has applied for patents in the BTK-1 project in countries and regions including Canada, the United States, Japan, South Korea, Hong Kong, Europe, Australia, and China. Currently, patent certificates have been obtained in Hong Kong, China, and Australia. The BTK2 project has obtained patent certificates in China and Japan. The company's BTK project alone has applied for more than 20 patent achievements in various countries and regions, providing strong support for protecting core technologies and supporting sustainable development of enterprises.